st irradiation, she would not receive the benefits of that final week of treatment, the boost therapy that, according to National Compre- hensive Cancer Network (NCCN) guidelines, is "recommended" for women like Paula, whose breast cancer is diagnosed before they are 50 years of age and who have axillary